Genprex Partners for Advanced Manufacturing of Innovative Diabetes Gene Therapy
Genprex, Inc., a clinical-stage gene therapy company focusing on revolutionary treatments for cancer and diabetes, has made a pivotal move by collaborating with a prominent U.S.-based Contract Development and Manufacturing Organization (CDMO). This partnership is instrumental for Genprex as it seeks to scale up the manufacturing of its diabetes gene therapy, transitioning from research-grade production to a clinical and commercial-ready stage. The decision will facilitate the production of their AAV-based diabetes therapy in a facility compliant with current Good Manufacturing Practices (cGMP).
With this collaboration, Genprex anticipates an acceleration in their timelines for IND-enabling preclinical studies and subsequent clinical trials. Ryan Confer, President and CEO of Genprex, remarked on the significance of this partnership, emphasizing the transition from academic manufacturing to partnering with an established CDMO known for its adherence to manufacturing standards. This step is aimed at propelling their diabetes gene therapy program toward crucial clinical evaluations that prioritize safety and efficacy, particularly essential factors for the impending toxicology studies.
The roadmap for manufacturing includes several key initiatives. Genprex aims to optimize production processes using cutting-edge AAV production technologies, enhancing efficiency. The CDMO’s capacity bioreactors will ensure that an ample supply of the drug is available for upcoming multi-center clinical trials. Furthermore, implementing robust quality control protocols for a potency assay and maintaining strict adherence to GMP standards will support future regulatory submissions effectively.
Genprex's diabetes gene therapy leverages an innovative approach by delivering the Pdx1 and MafA genes directly into the pancreas using an AAV vector. This gene therapy is designed to convert pancreatic alpha cells into functional beta-like cells capable of insulin production while evading the immune system. Early preclinical studies have demonstrated promising results, restoring normal blood glucose levels in Type 1 diabetes mouse models for extended periods. Additionally, in non-human primate models for Type 1 diabetes, the therapy has shown the potential to reduce insulin needs and improve glucose tolerance.
For Type 2 diabetes, where autoimmune responses are not a factor, the therapy has displayed the ability to rejuvenate and replenish exhausted beta cells, further showcasing its efficacy across varying diabetic conditions.
In pursuing these advanced therapies, Genprex continues to innovate and optimize its constructs, exploring alternative approaches, including a non-viral lipid nanoparticle delivery system for its diabetes therapy. This could open avenues for potential re-dosing strategies, optimizing patient treatment further.
Overall, Genprex is set on a path to redefine diabetes treatment methodologies through gene therapy, striving to offer newfound hope to patients dealing with Type 1 and Type 2 diabetes. Their commitment to developing advanced therapies is evident in their collaborations with leading institutions and experts in the field, aimed at overcoming the significant challenges in diabetic treatment landscapes. As the company pushes forward, interest from investors and stakeholders remains crucial, with Genprex encouraging proactive engagement via their website for updates on their groundbreaking work.
With this collaboration, Genprex anticipates an acceleration in their timelines for IND-enabling preclinical studies and subsequent clinical trials. Ryan Confer, President and CEO of Genprex, remarked on the significance of this partnership, emphasizing the transition from academic manufacturing to partnering with an established CDMO known for its adherence to manufacturing standards. This step is aimed at propelling their diabetes gene therapy program toward crucial clinical evaluations that prioritize safety and efficacy, particularly essential factors for the impending toxicology studies.
The roadmap for manufacturing includes several key initiatives. Genprex aims to optimize production processes using cutting-edge AAV production technologies, enhancing efficiency. The CDMO’s capacity bioreactors will ensure that an ample supply of the drug is available for upcoming multi-center clinical trials. Furthermore, implementing robust quality control protocols for a potency assay and maintaining strict adherence to GMP standards will support future regulatory submissions effectively.
Genprex's diabetes gene therapy leverages an innovative approach by delivering the Pdx1 and MafA genes directly into the pancreas using an AAV vector. This gene therapy is designed to convert pancreatic alpha cells into functional beta-like cells capable of insulin production while evading the immune system. Early preclinical studies have demonstrated promising results, restoring normal blood glucose levels in Type 1 diabetes mouse models for extended periods. Additionally, in non-human primate models for Type 1 diabetes, the therapy has shown the potential to reduce insulin needs and improve glucose tolerance.
For Type 2 diabetes, where autoimmune responses are not a factor, the therapy has displayed the ability to rejuvenate and replenish exhausted beta cells, further showcasing its efficacy across varying diabetic conditions.
In pursuing these advanced therapies, Genprex continues to innovate and optimize its constructs, exploring alternative approaches, including a non-viral lipid nanoparticle delivery system for its diabetes therapy. This could open avenues for potential re-dosing strategies, optimizing patient treatment further.
Overall, Genprex is set on a path to redefine diabetes treatment methodologies through gene therapy, striving to offer newfound hope to patients dealing with Type 1 and Type 2 diabetes. Their commitment to developing advanced therapies is evident in their collaborations with leading institutions and experts in the field, aimed at overcoming the significant challenges in diabetic treatment landscapes. As the company pushes forward, interest from investors and stakeholders remains crucial, with Genprex encouraging proactive engagement via their website for updates on their groundbreaking work.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.